Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Jan 7, 2025; 31(1): 100750
Published online Jan 7, 2025. doi: 10.3748/wjg.v31.i1.100750
Table 1 Baseline characteristics of the patients, n (%)

Overall (n = 256)
Conventional LLR (n = 150)
Novel LLR (n = 106)
P value
Age, year62.88 ± 10.5262.43 ± 11.0763.52 ± 9.710.414
Sex1.000
    Male130 (50.8)76 (50.7)54 (50.9)
    Female126 (49.2)74 (49.3)52 (49.1)
Pathological types0.707
    HCC176 (68.8)105 (70.0)71 (67.0)
    ICC80 (31.2)45 (30.0)35 (33.0)
BMI, kg/m223.77 ± 4.3023.90 ± 4.2923.59 ± 4.330.567
Hepatitis B/C virus0.119
    B212 (82.8)130 (86.7)82 (77.4)
    C9 (3.5)5 (3.3)4 (3.8)
    None35 (13.7)15 (10.0)20 (18.9)
Cirrhosis0.694
    No99 (38.7)56 (37.3)43 (40.6)
    Yes157 (61.3)94 (62.7)63 (59.4)
Comorbidities0.729
    No118 (46.1)71 (47.3)47 (44.3)
    Yes138 (53.9)79 (52.7)59 (55.7)
BCLC< 0.001
    022 (8.6)21 (14.0)1 (0.9)
    A230 (89.8)129 (86.0)101 (95.3)
    B2 (0.8)0 (0.0)2 (1.9)
    C2 (0.8)0 (0.0)2 (1.9)
CNLC0.650
    1A207 (80.9)119 (79.3)88 (83.0)
    1B45 (17.6)29 (19.3)16 (15.1)
    2A4 (1.6)2 (1.3)2 (1.9)
ECOG0.222
    0247 (96.5)147 (98.0)100 (94.3)
    19 (3.5)3 (2.0)6 (5.7)
Child-Pugh grade0.757
    A249 (97.3)145 (96.7)104 (98.1)
    B7 (2.7)5 (3.3)2 (1.9)
Preoperative ICG retention rate5.00 ± 2.063.57 ± 1.187.01 ± 1.14< 0.001
Conversion therapy1.000
    No253 (98.8)148 (98.7)105 (99.1)
    Yes3 (1.2)2 (1.3)1 (0.9)
Table 2 Intraoperative data for patients in both groups, n (%)

Overall (n = 256)
Conventional LLR (n = 150)
Novel LLR (n = 106)
P value
Tumor size, cm5.03 ± 2.884.01 ± 2.336.47 ± 2.96< 0.001
Tumor location31 (12.1)15 (10.0)16 (15.1)0.218
    S II23 (9.0)12 (8.0)11 (10.4)
    S III39 (15.2)27 (18.0)12 (11.3)
    S IV46 (18.0)32 (21.3)14 (13.2)
    S V37 (14.5)19 (12.7)18 (17.0)
    S VI33 (12.9)18 (12.0)15 (14.2)
    S VII36 (14.1)22 (14.7)14 (13.2)
    S VIII2 (0.8)2 (1.3)0 (0.0)
    S II/III9 (3.5)3 (2.0)6 (5.7)
Type of resection48 (18.8)36 (24.0)12 (11.3)0.051
    S5 + S6 + S7 + S843 (16.8)25 (16.7)18 (17.0)
    S2 + S3 + S438 (14.8)22 (14.7)16 (15.1)
    S6 + S735 (13.7)23 (15.3)12 (11.3)
    S6 + S7 + S5v + S8v38 (14.8)16 (10.7)22 (20.8)
    S727 (10.5)16 (10.7)11 (10.4)
    S7 + S827 (10.5)12 (8.0)15 (14.2)
Operative time, minute236.34 ± 81.08262.33 ± 83.90199.57 ± 60.37< 0.001
Blood loss298.57 ± 128.82363.34 ± 131.27206.92 ± 37.09< 0.001
Number of lesions0.165
    1251 (98.0)145 (96.7)106 (100.0)
    23 (1.2)3 (2.0)0 (0.0)
    32 (0.8)2 (1.3)0 (0.0)
Distance from major vessels0.944
    > 1 cm189 (73.8)110 (73.3)79 (74.5)
    < 1 cm67 (26.2)40 (26.7)27 (25.5)
Distance from liver capsule0.899
    < 1 cm128 (50.0)76 (50.7)52 (49.1)
    > 1 cm128 (50.0)74 (49.3)54 (50.9)
Preoperative resection volume, mL297.81 ± 50.90264.38 ± 31.98345.11 ± 31.40< 0.001
PRLV/TLV30.58 ± 10.0630.37 ± 10.2130.87 ± 9.890.697
Minimum surgical margin width, mm18.95 ± 6.3318.96 ± 6.2718.94 ± 6.450.984
Total pringle maneuver time, minute44.93 ± 10.5345.12 ± 10.4944.67 ± 10.640.737
ICG staining method0.887
    None176 (68.8)104 (69.3)72 (67.9)
    Negative staining52 (20.3)29 (19.3)23 (21.7)
    Positive staining28 (10.9)17 (11.3)11 (10.4)
Blood transfusion0.761
    No253 (98.8)149 (99.3)104 (98.1)
    Yes3 (1.2)1 (0.7)2 (1.9)
R0 resection Y256 (100.0)150 (100.0)106 (100.0)NA
Table 3 Postoperative data for patients in both groups, n (%)

Overall (n = 256)
Conventional LLR (n = 150)
Novel LLR (n = 106)
P value
90 days mortality
    No256 (100.0)150 (100.0)106 (100.0)
    Postoperative hospital stays, day5.36 ± 1.895.90 ± 2.174.59 ± 1.02< 0.001
Readmission1.000
    No255 (99.6)149 (99.3)106 (100.0)
    Yes1 (0.4)1 (0.7)0 (0.0)
Recurrence0.636
    No254 (99.2)148 (98.7)106 (100.0)
    Yes2 (0.8)2 (1.3)0 (0.0)
Follow up months10 (5, 15)10 (5, 15)11 (5, 16)0.346
Liver failure1.000
    No255 (99.6)149 (99.3)106 (100.0)
    Yes1 (0.4)1 (0.7)0 (0.0)
Ascites0.382
    No253 (98.8)147 (98.0)106 (100.0)
    Yes3 (1.2)3 (2.0)0 (0.0)
Clavien-Dindo complication grade0.636
    < IIIa254 (99.2)148 (98.7)106 (100.0)
    ≥ IIIa2 (0.8)2 (1.3)0 (0.0)